ℹ Important Notice: Pharma products are sold and shipped exclusively to registered medical professionals at verified medical premises.
Non-approved buyers:
Complete our Online POM Form, and we will notify you once your account is Pharma approved.
Powder and solvent for suspension for injection, sustained release formulation.
Therapeutic indications
• Treatment of patients with locally advanced, non-metastatic prostate cancer, as an alternative to surgical castration (see section 5.1).
• Treatment of metastatic prostate cancer.
• As adjuvant treatment to radiotherapy in patients with high-risk localised or locally advanced prostate cancer.
• As neoadjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced prostate cancer.
• As adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression.
• Treatment of endometriosis.
•Treatment of precocious puberty (onset before 8 years in girls and 10 years in boys).
Features
Nature and contents of container
• A type I, 4mL capacity glass vial with an elastomer stopper and an aluminium cap containing the powder.
• A type I, 3mL capacity glass ampoule containing 2mL of the suspension vehicle.
• Box containing 1 vial and 1 ampoule with 1 syringe and 2 needles.
Special precautions for storage
• Do not store above 25°C. Keep container in the outer carton.
Shelf life
• The product should be used immediately after reconstitution.
Patient Information Leaflet
https://www.medicines.org.uk/emc/files/pil.780.pdf
| Presentation | Vial |
| Presentation | Vial |
| Pack size | 1 |
| Presentation | Vial |
